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Aim: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties 
of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical 
timolol, oral acetazolamide, and no treatment.
Methods: A prospective, randomized, investigator-blind, parallel-group study was conducted 
in 73 eyes of 52 subjects. Subjects received a single dose of IV paracetamol (1 g), oral acetazol-
amide (250 mg), topical timolol (0.5%, one drop), or no treatment. Baseline IOP was measured, 
and the measurement was repeated at 1, 2, 4, and 6 hours after treatment.
Results: Paracetamol reduced IOP from baseline by -10.8% (95% confidence interval 
[CI]: -4.9% to -16.8%, P=0.146) at 1 hour, -13.3% (95% CI: -8.3% to -18.4%, P=0.045) 
at 2 hours, -11.8% (95% CI: -5.5% to -18.4%, P=1.000) at 4 hours, and -23.9% (95% 
CI: -17.8% to -30.1%, P=0.006) at 6 hours after treatment. In the no-treatment group, the 
change was -2.9% (95% CI: +1.0% to -6.7%, P= referent) at 1 hour, -2.1% (95% CI: +2.9% 
to -7.2%, P= referent) at 2 hours, -7.6% (95% CI: -3.9% to -11.2%, P= referent) at 4 hours, 
and -6.9% (95% CI: -3.6% to -10.2%, P= referent) at 6 hours. Acetazolamide reduced IOP 
by -18.8% (95% CI: -12.7% to -24.8%, P=0.000) at 1 hour, -26.2% (95% CI: -18.2% 
to -34.2%, P=0.001) at 2 hours, -24.6% (95% CI: -16.9% to -32.3%, P=0.000) after 4 hours, 
and -26.9% (95% CI: -19.6% to -34.3%, P=0.000) 6 hours after treatment. Timolol reduced 
IOP by -31.2% (95% CI: -26.7% to -35.7%, P=0.000) at 1 hour, -27.7% (95% CI: -20.7% 
to -34.8%, P=0.000) at 2 hours, -28.7% (95% CI: -21.1% to -36.2%, P=0.000) at 4 hours, 
and -21.3% (95% CI: -13.4% to -30.0%, P=0.030) at 6 hours after treatment. The average 
change in IOP for the no-treatment group was -4.8% (95% CI: -2.6% to -6.9%, P= referent). It 
was -15.7% (95% CI: -9.3% to -22.1%, P=0.021) for paracetamol, -23.1% (95% CI: -16.4% 
to -29.8%, P=0.000) for acetazolamide, and -25.3% for the timolol group (95% CI: -19.4% 
to -31.2%, P=0.000). The maximal change in IOP for the no-treatment group was -9.2% (95% 
CI: -3.2% to -15.3%, P= referent). It was -25.9% (95% CI: -16.6% to -35.2%, P=0.009) for 
paracetamol, -33.8% (95% CI: -25.5% to -42.1%, P=0.000) for acetazolamide, and -36.8% 
(95% CI: -31.0% to -42.5%, P=0.000) for the timolol group.
Conclusion: Intravenously administered paracetamol shows IOP-lowering properties over the 
first 6 hours after administration. Clinicians performing IOP measurements in patients who have 
received IV paracetamol in the preceding 6 hours should interpret these measurements with cau-
tion. Further studies are needed to investigate the IOP-changing properties of paracetamol.
Keywords: AM404, anandamide, endocannabinoid, ocular hypotensive
Introduction
Paracetamol has already shown theoretical and clinical potential as an ocular 
hypotensive possibly as a result of its interactions with the endocannabinoid system 
(ECS).1–3 Intravenous (IV) paracetamol is often used in the perioperative period as an 
opioid-sparing analgesic in the adult and pediatric population, and ophthalmologists 
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may encounter patients, during procedures and thereafter, 
who have recently received IV paracetamol.4,5 The intraocular 
pressure (IOP)-lowering properties of anesthetic gasses, and 
other anesthetic agents, have been well studied, and clinicians 
interpret IOP measurements taken after their administration 
with caution.6,7
IV paracetamol has a proven high analgesic potency and 
rapid analgesic effect which begged the question of whether 
it might also result in a change in IOP in accordance with its 
interaction with the ECS.4
The exact mechanism of action of paracetamol is after 
137 years still elusive, although we do know that it at least 
inhibits the activity of enzymes cyclooxygenase-1 and 
cyclooxygenase-2 and reduces the synthesis of prostaglandins 
in the central nervous system.8
The ECS is a system of neurotransmitters and receptors 
with a remarkable representation in many human tissues 
including the eye.9–13 In 2005, it was molecularly proven that 
paracetamol acts as a prodrug for the indirect cannabinomimetic 
AM404. Paracetamol is deacetylated in the brain and spinal 
cord to p-aminophenol, and with the action of fatty acid amide 
hydrolase undergoes conjugation with arachidonic acid to 
form AM404. This finding by Högestätt et al and Ottani et al 
subsequently expanded the knowledge of the mechanism of 
action of paracetamol by indicating that it stimulates the ECS by 
increasing the levels of anandamide through reuptake inhibition 
by AM404.1,2 Anandamide is a potent ocular hypotensive, and 
the question arises as to whether paracetamol would, as other 
cannabinomimetics do, also reduce IOP.12,13
Topical timolol and oral acetazolamide are regarded 
as the gold standard topical and oral hypotensive agents, 
respectively, and are both well studied. Clinicians expect to 
observe a certain level of reduction in IOP in the few hours 
after their administration. How their IOP-changing properties 
in the first 6 hours after administration compare with that of 
paracetamol has not previously been compared.14 The main 
reason for including these comparisons into the study was to 
give clinical perspective to any possible change in IOP.
To our knowledge, this is thus the first study to investi-
gate the IOP-changing properties of a single standard dose 
of IV paracetamol in comparison with that of oral acetazo-
lamide, topical timolol, and no treatment. The study would 
not pursue an investigation into the therapeutic efficacy of 
IV paracetamol as an IOP-lowering agent.
Materials and methods
The study was approved by the Human Research Ethics 
Committee of the Faculty of Medicine and Health Sciences 
of the Stellenbosch University, Cape Town, and adhered 
to the tenets of the Declaration of Helsinki. Proper written 
informed consent was obtained from all participants.
A general physical and full ocular examination was per-
formed on all participants.
Inclusion criteria were consenting adults of any sex and 
ethnicity of 18–75 years of age with a body weight .40 kg 
and body mass index (BMI) 18.5–37 kg/m2 inclusive.
External exclusion criteria were the following: known 
hypersensitivity or idiosyncratic reactions to paracetamol, 
acetazolamide, or timolol; use of paracetamol or any systemic 
medications (including β-blockers) known to lower IOP, 
within 4 weeks of the study; any known clinically significant 
systemic (eg, gastrointestinal, hepatic, or renal) disease or 
other condition known to interfere with the absorption, dis-
tribution, metabolism, or excretion of drugs; COPD, asthma, 
or cardiac contraindications for β-blocker use; pregnancy or 
breastfeeding; females of childbearing potential not using 
medically accepted contraceptive measures; participation 
in a clinical study of any investigational product 1 month 
prior to the study or during the study; and the presence of 
an uncontrolled psychiatric condition.
Ocular exclusion criteria were the following: baseline 
IOP $22 mmHg or IOP #10 mmHg, history of glaucoma, 
signs of glaucomatous optic neuropathy irrespective of 
IOP (assessed by disc appearance, IOP, and if indicated, 
optical coherence tomography analysis of optic nerve rim 
and retinal nerve fiber layer [Carl Zeiss Meditec AG, Jena, 
Germany] and formal 24-2 visual field analysis [Carl Zeiss 
Meditec AG]), iridocorneal angles less than grade 3 as with 
Schaefer’s method, or the presence of peripheral anterior 
synechiae as determined with gonioscopy; contact lenses 
worn within 3 weeks of starting of study; ocular disease 
excluding uncomplicated cataract; and previous ocular sur-
gery or trauma in the study eye.
Participants were assigned to the four treatment arms 
through ratio randomization with a third of eyes each to the 
paracetamol and no-treatment groups, and a sixth of eyes 
each to the acetazolamide and timolol groups.
The no-treatment group received no treatment. The par-
acetamol group received a single dose of 1 g IV paracetamol 
(Perfalgan®; Bristol-Myers Squibb, New York City, NY, 
USA). The acetazolamide group received a single oral dose 
of 250 mg acetazolamide (Diamox®; Litha Pharma, Midrand, 
South Africa). The timolol group received a single drop of 
0.5% timolol maleate (Glaucosan®; Sandoz International 
GmbH, Holzkirchen, Germany) followed by 2 minutes of 
punctal occlusion. Participants were admitted to a general 
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ophthalmology hospital ward and subjected to the same 
hospital diet and low level of physical activity.
IOP was measured with a calibrated Goldmann applanation 
tonometer (Haag-Streit® AT-900 , Haag-Streit, Koeniz, Switzer-
land) by a single observer (HvdH) experienced in applanation 
tonometry. The observer was masked to participant’s treatment 
regimens, and IOP measurements were recorded. This was done 
by appropriately adjusting the tonometer dial to the estimated 
value and allowing a second observer to record IOP values 
and then scrambling the tonometer dial thereafter. For an IOP 
reading to be accepted as valid, two subsequent readings had to 
be ,2 mmHg apart. The average of these two valid measure-
ments was calculated and used as the final value.
IOP was again measured at 1, 2, 4, and 6 hours after 
treatment.
Primary outcomes included percentage change in IOP 
from baseline at 1, 2, 4, and 6 hours after treatment for each 
of the four groups. For every eye, the average and maximal 
percentage changes in IOP were calculated.
statistical analysis
IBM SPSS version 23 was used for analysis. A P-value ,0.05 
was considered as statistically significant. One-way analysis 
of variance testing was used to compare mean values between 
the four groups, with Bonferroni-adjusted post hoc tests. 
Pearson’s chi-square tests were used to compare proportions 
between the four groups. Multilevel mixed linear regression 
models were used to assess the determinants of change in 
IOP over time while adjusting for age, BMI, and sex. The 
interaction between time and treatment group was taken as 
the differential treatment effect over time.
Results
Demographic profile
Demographic results are presented in Table 1. Ten partici-
pants were excluded from the study, prior to observation, 
because of oral paracetamol and/or oral β-blocker use 
4 weeks prior to or during the study period. One subject 
voluntarily withdrew from the study, after completion of 
the hour-2 IOP measurement, because of personal inconve-
nience. There were no serious adverse events.
Seventy-three eyes of 52 subjects were included in the 
study. Fifteen eyes were excluded at the 6-hour time point, 
as their observations were not made close enough to the 
specific time point. The loss of data for this time point was 
adequately addressed by statistical modeling.
Change in iOP over time
There was no significant difference between the baseline IOP 
of the groups (P=0.413; Table 2).
The change in IOP from baseline for the no-treatment 
group was -2.9% at 1 hour, -2.1% at 2 hours, -7.6% at 
4 hours, and -6.9% at 6 hours after treatment (Table 2; 
Figure 1).
Paracetamol reduced IOP from baseline by -10.8% 
(P=0.146) at 1 hour, -13.3% (P=0.045) at 2 hours, -11.8% 
(P=1.000) at 4 hours, and -23.9% (P=0.006) at 6 hours after 
treatment.
In the acetazolamide group, the reduction was -18.8% 
(P=0.000) at 1 hour, -26.2% (P=0.000) at 2 hours, -24.6% 
(P=0.001) at 4 hours, and -26.9% (P=0.000) at 6 hours after 
treatment.
Timolol reduced IOP by -31.2% (P=0.000) at 
1 hour, -27.7% (P=0.000) at 2 hours, -28.7% (P=0.000) at 
4 hours, and –21.3% (P=0.030) at 6 hours after treatment.
average change in iOP
The average change in IOP from baseline over the first 
6 hours after treatment for the no-treatment group was -4.8% 
(Table 2; Figure 2). It was -15.7% (P=0.021) for paraceta-
mol, –23.1% (P=0.000) for acetazolamide, and -25.3% 
(P=0.000) for timolol. There was no statistically significant 
Table 1 Descriptive statistics summary of demographics and number of participants in each group with (±) standard deviation
Characteristic No Treatment Paracetamol Acetazolamide Timolol
n=24 n=20 n=17 n=12
Male 10 9 7 4
Female 14 11 10 8
Black 9 3 7 2
Mixed race 12 14 9 9
Caucasian 3 3 1 1
age (years) 43±15 (range, 22–75) 61±13 (range, 29–74) 57±15 (range, 26–74) 60±15 (range, 24–71)
Weight (kg) 69±15 (range, 51–102) 69±10 (range, 56–96) 72±17 (range, 46–99) 72±19 (range, 40–106)
BMi (kg/m2) 26±5 (range, 21–37) 26±4 (range, 20–32) 27±5 (range, 19–34) 26±5 (range, 16–34)
Abbreviation: BMi, body mass index.
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difference in average reduction in IOP when the paracetamol 
and acetazolamide groups were compared with each other 
(P=0.262), which was also the case for the paracetamol and 
timolol groups (P=0.094).
Maximal change in iOP
The maximal change in IOP from baseline within the first 
6 hours after treatment for the no-treatment group was -9.2% 
(Table 2; Figure 3). It was -25.9% (P=0.009) for paracetamol, 
-33.8% (P=0.000) for acetazolamide, and -36.8% (P=0.000) 
for timolol. There was no statistically significant difference in 
maximal reduction in IOP when the paracetamol and aceta-
zolamide groups were compared with each other (P=0.691), 
which was also the case for the paracetamol and timolol 
groups (P=0.268).
Discussion
The study aimed to investigate a possible novel pharma-
cological pleiotropic property of IV paracetamol and did 
not aim to investigate paracetamol’s ocular hypotensive 
therapeutic efficacy or suggest it as an alternative glau-
coma treatment. For this reason, a “No Treatment” arm 
was included instead of a placebo arm, to more accurately 
replicate practical clinical scenarios, and acetazolamide and 
timolol were included to give clinical perspective to the 
magnitude of IOP change.
In this study, the administration of 1 g IV paraceta-
mol was followed by a trend toward a reduction in IOP 
that was statistically significant at 2 and 6 hours after 
administration. Although not statistically significant, 
there was a reduction of 10.8% in IOP after 1 hour in the 
Table 2 Summary of baseline IOP, change in IOP from group-specific baseline (%) at each time point, average change in IOP, and 
maximal change in IOP with 95% CI
No Treatment Paracetamol Acetazolamide Timolol
Baseline iOP (mmhg) 15.7 (95% CI: 14.3 to 17.1) 14.8 (95% CI: 13.6 to 15.9) 14.5 (95% CI: 12.7 to 16.3) 14.3 (95% CI: 12.8 to 15.8)
Change in iOP after 
1 hour (mmhg)
-2.9% (95% CI: 1.0% to 
-6.7%), referent
-10.8% (95% CI: -4.9% to 
-16.8%), P=0.146
-18.8% (95% CI: -12.7% 
to -24.8%), P=0.000
-31.2% (95% CI: -26.7% to 
-35.7%), P=0.000
Change in iOP after 
2 hours (mmhg)
-2.1% (95% CI: 2.9% to 
-7.2%), referent
13.3% (95% CI: -8.3% to 
-18.4%), P=0.045
-26.2% (95% CI: -18.2% 
to -34.2%), P=0.000
-27.7% (95% CI: -20.7% to 
-34.8%), P=0.000
Change in iOP after 
4 hours (mmhg)
-7.6% (95% CI: -3.9% to 
-11.2%), referent
-11.8% (95% CI: -5.5% to 
-18.1%), P=1.000
-24.6% (95% CI: -16.9% 
to -32.3%), P=0.001
-28.7% (95% CI: -21.1% to 
-36.2%), P=0.000
Change in iOP after 
6 hours (mmhg)
-6.9% (95% CI: -3.6% to 
-10.2%), referent
-23.9% (95% CI: -17.8% 
to -30.1), P=0.006
-26.9% (95% CI: -19.6% 
to -34.3%), P=0.000
-21.3% (95% CI: -13.4% to 
-30.0%), P=0.030
average change in iOP 
over 6 hours (mmhg)
-4.8% (95% CI: -2.6% to 
-6.9%), referent
-15.7% (95% CI: -9.3% to 
-22.1%), P=0.021
-23.1% (95% CI: -16.4% 
to -29.8%), P=0.000
-25.3% (95% CI: -19.4% to 
-31.2%), P=0.000
Maximal change in iOP 
within 6 hours (mmhg)
-9.2% (95% CI: -3.2% to 
-15.3%), referent
-25.9% (95% CI: -16.6% 
to -35.2%), P=0.009
-33.8% (95% CI: -25.5% 
to -42.1%), P=0.000
-36.8% (95% CI: -31.0% to 
-42.5%), P=0.000
Abbreviations: IOP, intraocular pressure; CI, confidence interval.
±
±
±
±
±
±

±
±

KRXU KRXUV KRXUV KRXUV
0HD
QSH
UFHQ
WDJH
FKD
QJH
LQ,
23
1R7UHDWPHQW 3DUDFHWDPRO$FHWD]RODPLGH 7LPRORO
Figure 1 Mean percentage change in iOP at all time points.
Abbreviation: iOP, intraocular pressure.
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Figure 2 Mean percentage change in IOP over the first 6 hours after treatment. 
Abbreviation: iOP, intraocular pressure.
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paracetamol group when compared to a 2.9% reduction 
in the No Treatment arm.
There was no significant difference in the IOP response 
when ethnicity, age, or BMI was considered.
The average change in IOP for the paracetamol group 
over the first 6 hours was -15.7%, and the maximal change 
was -25.9%, which was statistically significant when com-
pared to the no-treatment group. In the No Treatment arm, 
the 95% confidence intervals (CIs) included a rise in IOP 
of +1.0% and +2.9% at 1 and 2 hours, respectively. Parac-
etamol and the other two treatment arms showed no such 
expected change according to their 95% CI ranges.
The average and maximal reduction in IOP produced 
by paracetamol was inferior to that of timolol and acetazo-
lamide but statistically significantly more than that of the 
no-treatment group.
In our no-treatment group, there was an average reduc-
tion in IOP over the first 6 hours of -4.8% which is similar 
to the -5% found in a meta-analysis of glaucoma therapies 
and strengthens the validity of our no-treatment group find-
ings.14 This expected diurnal phenomenon was adequately 
accounted for by appropriate statistical analysis. Similarly, 
the IOP reduction we observed with topical timolol compared 
well with previous studies by Katz et al and Zimmerman and 
Kaufman where they showed a reduction in IOP by -16.8% 
at 1 hour, -26.3% at 2 hours, and -27.8% at 5 hours, and 
by -34.4% at 2 hours, -44.3.3% at 4 hours, and -27.8% at 
5 hours, respectively.15,16
IOP in the paracetamol group showed a downward trend 
up to 6 hours after treatment, and the reduction in IOP at that 
point in the paracetamol group was similar to the other two 
active treatment arms (paracetamol/acetazolamide, P=1.000; 
and paracetamol/timolol, P=1.000).
In general, the IOP-lowering response of a single standard 
dose of IV paracetamol was inferior to that of both topical 
timolol and oral acetazolamide.
The need for a follow-up study with repeated doses of 
IV paracetamol and observations beyond 6 hours is evident. 
Such multiple doses have been proven safe as the safety 
profile of IV paracetamol compares well with the oral and 
rectal formulations, and doses of up to 4 g daily are rarely 
associated with hepatotoxicity.4,5
Sevoflurane and propofol, among other anesthetic drugs, 
are known to reduce IOP and should be avoided when per-
forming tonometry in patients under general anesthesia.6,7 
Similar to sevoflurane and propofol, our results show that IV 
paracetamol shows a trend toward reducing IOP. Clinicians 
performing tonometry on patients under general anesthesia 
should consider enquiring from the anesthetist as to whether 
IV paracetamol was recently given to the patients before 
interpreting IOP measurements as patients increasingly 
receive paracetamol in the perianesthetic period.4
Although not a direct finding or conclusion of the study, 
our results could be explained by the molecular basis of the 
mechanism of action of paracetamol as proposed by Högestätt 
et al and Ottani et al.1,2
Although probably not widely known, the molecular basis 
of the ocular hypotensive properties of paracetamol through 
the ECS is well documented, and the ocular hypotensive 
properties of its major ligand, anandamide, and the CB1 
receptor’s abundant distribution in the eye are thoroughly 
reported.9–13
If paracetamol indeed interacts with the ECS, as our find-
ings might support, it may influence our understanding of 
concurrent paracetamol and antiglaucoma medication use as 
cannabinomimetics, and some commonly used antiglaucoma 
therapies employ similar molecular mechanics to reduce 
IOP, which may influence their efficacy.17,18 Further studies 
to address the theoretical pharmacodynamic interaction of 
paracetamol with topical β-blockers and prostamides may 
also be warranted, as many patients on glaucoma therapy, 
like their non-glaucomatous counterparts, use prescribed or 
self-medicating paracetamol.
A high correlation between levels of paracetamol in the 
serum and levels in the tear film has been shown; this effec-
tively means that the use of systemic paracetamol leads to 
an unintended ocular topical application thereof which raises 
interesting questions regarding the ocular hypotensive effects 
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Figure 3 Maximal percentage change in IOP over the first 6 hours after treatment.
Abbreviation: iOP, intraocular pressure.
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of topically applied paracetamol as it has been shown to read-
ily cross the cornea into the anterior chamber.3,19
Finally, apart from its role in the regulation of IOP, the 
ECS has also been implicated in many other ocular condi-
tions and physiological processes.20–27 Whether paracetamol, 
through its apparent association with the ECS, has an effect 
on these is yet to be investigated.
Although our study did not aim to clinically vindicate 
the molecular mechanism of action of paracetamol, our 
findings may provide clinical support for the proposal that 
paracetamol is indeed a cannabinomimetic.
Limitations
The findings are a result of a single standard dose of IV 
paracetamol which limits its application to predicting 
whether, and by how much, chronic paracetamol use or 
successive doses of IV paracetamol would change IOP. The 
introduction of IV paracetamol to clinical practice expands 
its clinical relevance to more than just that of its chronic oral 
administration. For the purposes of replicating the adminis-
tration of IV paracetamol in the perioperative period, a single 
standard dose was accepted as realistic to this increasingly 
common scenario.
The exclusion of pediatric patients from the cohort limits 
the application of the results to an adult population. Whether 
IV paracetamol, used in pediatric pain management, changes 
IOP in this special population is still to be investigated.
Not investigating the possible interactions of paracetamol 
with common topical glaucoma agents is not seen as a limi-
tation of the study but rather an important clinical question 
that needs to be addressed by future studies.
Conclusion
Intravenously administered paracetamol shows IOP-lowering 
properties over the first 6 hours after administration. Clini-
cians performing IOP measurements in patients who have 
received IV paracetamol in the preceding 6 hours should 
interpret these measurements with caution. Further studies 
are needed to investigate the IOP-changing properties of 
paracetamol.
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